A non-nucleotide agonist that binds covalently to cysteine residues of STING
-
- Matsumoto Kentaro
- Laboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University
-
- Ni Shenwei
- Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo
-
- Arai Hiroyuki
- Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo
-
- Toyama Takashi
- Laboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical Sciences, Tohoku University
-
- Saito Yoshiro
- Laboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical Sciences, Tohoku University
-
- Suzuki Takehiro
- Biomolecular Characterization Unit, Technology Platform Division, RIKEN Center for Sustainable Resource Science
-
- Dohmae Naoshi
- Biomolecular Characterization Unit, Technology Platform Division, RIKEN Center for Sustainable Resource Science
-
- Mukai Kojiro
- Laboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University
-
- Taguchi Tomohiko
- Laboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University
この論文をさがす
説明
<p>Stimulator of interferon genes (STING) is an ER-localized transmembrane protein and the receptor for 2',3'-cyclic guanosine monophosphate–adenosine monophosphate (cGAMP), which is a second messenger produced by cGAMP synthase (cGAS), a cytosolic double-stranded DNA sensor. The cGAS-STING pathway plays a critical role in the innate immune response to infection of a variety of DNA pathogens through the induction of the type I interferons. Pharmacological activation of STING is a promising therapeutic strategy for cancer, thus the development of potent and selective STING agonists has been pursued. Here we report that mouse STING can be activated by phenylarsine oxide (PAO), a membrane permeable trivalent arsenic compound that preferentially reacts with thiol group of cysteine residue (Cys). The activation of STING with PAO does not require cGAS or cGAMP. Mass spectrometric analysis of the peptides generated by trypsin and chymotrypsin digestion of STING identifies several PAO adducts, suggesting that PAO covalently binds to STING. Screening of STING variants with single Cys to serine residues (Ser) reveals that Cys88 and Cys291 are critical to the response to PAO. STING activation with PAO, as with cGAMP, requires the ER-to-Golgi traffic and palmitoylation of STING. Our results identify a non-nucleotide STING agonist that does not target the cGAMP-binding pocket, and demonstrate that Cys of STING can be a novel target for the development of STING agonist.</p><p>Key words: STING agonist, cysteine modification, innate immunity, phenylarsine oxide</p>
収録刊行物
-
- Cell Structure and Function
-
Cell Structure and Function 48 (1), 59-70, 2023
日本細胞生物学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390576601793388928
-
- NII書誌ID
- AA0060007X
-
- ISSN
- 13473700
- 03867196
-
- NDL書誌ID
- 033355732
-
- PubMed
- 36575042
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可